Novel CCK-B receptor agonists: Diketopiperazine analogues derived from CCK4 bioactive conformation

Regulatory Peptides

Volumn 65, Issue 1, 1996, Pages 3-9

  Weng, Jian Hui ^a   Bado, André ^b   Garbay, Christiane ^a   Roques, Bernard P ^a  

^a Laboratoire de Pharmacochimie   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

CCK B agonist; Cholecystokinin; Diketopiperazine; Gastric acid secretion; Inositol phosphates liberation; Molecular modeling

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ DERIVATIVE; CHOLECYSTOKININ OCTAPEPTIDE; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; PENTAGASTRIN; PIPERAZINEDIONE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; GUINEA PIG; HAMSTER; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PANCREAS; PRIORITY JOURNAL; RAT; STOMACH SECRETION;

ANIMALIA; CAVIA PORCELLUS; CRICETINAE; SUS SCROFA;

EID: 0343484482     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/0167-0115(96)00065-1     Document Type: Article

References (39)

1. [1] Beinfeld, M.C., Cholecystokinin in the central nervous system: a minireview, Neuropeptides, 3 (1983) 411-427.
2. [2] Hökfelt, T., Skirboll, L., Everitt, B., Meister, B., Brownstein, M., Jacobs, T., Faden, A., Kuga, S., Goldstein, M., Marstein, R. et al., Distribution of cholecystokinin-like immunoreactivity in the nervous system. Co-existence with classical neurotransmitters and other neuropeptides, Ann. NY Acad. Sci., 448 (1985) 255-274.
3. [3] Baber, N.S., Dourish, C.T. and Hill, D.R., The role of CCK, caerulein and CCK antagonists in nociception, Pain, 39 (1989) 307-328.
4. [4] Faris, P.L., Komisaruk, B.R., Watkins, L.R. and Mayer, D.J., Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia, Science, 219 (1983) 310-312.
5. [5] Noble, F., Derrien, M. and Roques, B.P., Modulation of opioid antinociception by CCK at the supraspinal level: Evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain, Br. J. Pharmacol., 109 (1993) 1064-1070.
6. [6] Daugé, V., Steimes, P., Derrien, M., Beau, N., Roques, B.P. and Féger, J., CCK8 effects on motivational and emotional states of rats involve CCK-A receptors of the postero-median part of the nucleus accumbens, Pharmacol. Biochem. Behav., 34 (1989) 157-163.
7. [7] Singh, L., Lewis, A.S., Field, M.J., Hughes, J. and Woodruff, G.N., Evidence for an involvement of the brain cholecystokinin B receptor in anxiety, Proc. Natl. Acad. Sci. USA, 88 (1991) 1130-1133.
8. [8] Itoh, S. and Lal, H., Influence of cholecystokinin and analogues on memory process, Drug Dev. Res., 21 (1990) 257-276.
9. [9] Wang, R.Y., Cholecystokinin, dopamine, and schizophrenia: Recent progress and current problems, Ann. N.Y. Acad. Sci., 537 (1988) 362-379.
10. [10] Schalling, M., Friberg, K., Serrogy, K., Riederer, P., Schiffman, S.N., Mailleux, P., Vanderhaeghen, J.J., Kuga, S., Goldstein, M., Kitahama, K., Luppi, P.H., Jouvet, M. and Hökfelt, T., Analysis of expression of cholecystokinin in the ventral mesencephalon of several species and in human schizophrenia, Proc. Natl. Acad. Sci. USA, 87 (1990) 8427-8431.
11. [11] Dourish, C.T., Hawley, D. and Iversen, S.D., Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by cholecystokinin antagonist L-364,718. Eur. J. Pharmacol., 147 (1988) 469-472.
12. [12] Wiesenfeld-Hallin, Z., Xu, X.J., Hughes, J., Horwell, D.C. and Hökfelt, T., PD-134,308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes, Proc. Natl. Acad. Sci. USA, 87 (1990) 7105-7109.
13. [13] Valverde, O., Maldonado, R., Fournié-Zaluski, M.C. and Roques, B.P., Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins, J. Pharmacol. Exp. Ther., 270 (1994) 77-88.
14. [14] Hughes, J., Boden, P., Costall, B., Domeney, A., Kelly, E., Horwell, D.C., Hunter, J.C., Pinnock, R.D. and Woodruff, G.N., Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity, Proc. Natl. Acad. Sci. USA, 87 (1990) 6728-6732.
15. [15] Horwell, D.C., Hughes, J., Hunter, J.C., Pritchard, M.C., Richardson, R.S., Roberts, E. and Woodruff, G.N., Rationally designed 'Dipeptoid' analogues of CCK, α-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties. J. Med. Chem., 34 (1991) 404-414.
16. [16] Daugé, V., Ladurelle, N., Derrien, M., Durieux, C. and Roques, B.P., Potential therapeutical applications of CCK antagonists in anxiety and panic disorders. In M. Hamon, H. Ollat and M.H. Thiébot (Eds.), Anxiety: Neurobiology Clinic and Therapeutic Perspectives, Vol. 232. J. Libbey Eurotext, 1993, pp. 167-176.
17. [17] Derrien, M., Durieux, C. and Roques, B.P., Antidepressant-like effects of CCK-B antagonists in mice: antagonism by naltrindole, Br. J. Pharmacol., 111 (1994) 956-960.
18. [18] Hernando, F., Fuentes, J.A., Roques, B.P. and Ruiz-Gayo, M., The CCK-B receptor antagonist, L-365.260, elicites antidepressant-type effects in the forced-swim test in mice, Eur. J. Pharmacol., 261 (1994) 257-263.
19. [19] Crawley, J.N., Cholecystokinin-dopamine interactions, Trends Pharmacol. Sci., 12 (1991) 232-236.
20. 8 and of the CCK-B-selective agonist BC264 on extracellular dopamine content in the anterior and posterior nucleus accumbens: a microdialysis study in freely moving rats, Brain Res., 628 (1993) 254-262.
21. [21] Crawley, J.N., Stivers, J.A., Blumstein, L.K. and Paul, S.M., Cholecystokinin potentiates dopamine-mediated behaviors: evidence for modulation specific to a site of coexistence, J. Neurosci., 5 (1985) 1972-1983.
22. [22] Studler, J.M., Reibaud, M., Herve, D., Blanc, G., Glowinski, J. and Tassin, J.P., Opposite effects of sulfated cholecystokinin on DA-sensitive adenylate cyclase in two areas of the rat nucleus accumbens, Eur. J. Pharmacol., 126 (1986) 125-128.
23. [23] Marshall, F.H., Barnes, S., Hughes, J., Woodruff, G.N. and Hunter, J.C., Cholecystokinin modulates the release of dopamine efflux from the anterior and posterior nucleus accumbens by two different mechanisms, J. Neurochem., 56 (1991) 917-922.
24. [24] Ladurelle, N., Keller, G., Blommaert, A., Roques, B.P. and Daugé, V., BC 264, a CCK-B agonist, does not induce anxiogenic-like responses, but exhibits dopamine-dependent effects and memory facilitation after intraperitoneal injection in rats, Eur. J. Neurosci. (1996) submitted.
25. [25] Daugé, V. and Roques, B.P., Opioid and CCK systems in anxiety and reward. In: J. Bradwejn and E. Vasar (Eds.), Cholecystokinin and Anxiety: from Neuron to Behavior. R.G. Landes, 1995, pp. 151-171.
26. 3H]cholecystokinin 8 as a radioligand, J. Neurosci., 4 (1984) 1021-1033.
27. [27] de Montigny, C., Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers, Arch. Gen. Psychiatry, 46 (1989) 511-517.
28. [28] Bradwejn, J., Koszycki, D. and Shriqui, C., Enhanced sensivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioural findings, Arch. Gen. Psychiatry, 48 (1991) 603-610.
29. 2, Biopolymers, 34 (1994) 155-169.
30. [30] Durieux, C., Coppey, M., Zajac, J.M. and Roques, B.P., Occurrence of two cholecystokinin binding sites in guinea pig brain cortex, Biochem. Biophys. Res. Commun., 137 (1986) 1167-1173.
31. [31] Wennogle, L.P., Steel, D.L. and Petrack, B., Characterization of central cholecystokinin receptors using a radiodinated probe, Life Sci., 36 (1985) 1485-1492.
32. 50) of an enzymatic reaction, Biochem. Pharmacol., 22 (1973) 3099-3108.
33. [33] McCort, I., Ducos, B., Meudal, H., Goudreau, N., Jagerschmidt, A. and Roques, B.P., Synthesis and biochemical properties of conformationally constrained analogs of the potent and selective CCK-B antagonist RB 210, J. Med. Chem. (1996) submitted.
34. [34] Berridge, M.J., Dawson, R.M.C., Downes, C.P., Heslop, J. and Irvine, R.F., Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinosides, Biochem. J., 212 (1983) 473-482.
35. [35] Robein, M.J., De la Mare, M.C., Dubrasquet, M. and Bonfils, S., Utilization of the perfused stomach in anesthetized rats to study the inhibitory effect of stomatostatin in gastric acid secretion, Agents Actions, 9 (1980) 415-421.
36. [36] Ghosh, M.H. and Schild, H., Continuous recording of acid secretion in the rat, Br. J. Pharmacol. (Chemoth.), 13 (1959) 54-61.
37. [37] Lai, K.S., Studies of gastrin, Part 1. A method of biological assay of gastrin, Gut, 5 (1964) 327-333.
38. 2 derivatives, Bioorg. Med. Chem. (1995) in press.
39. 4, Peptides, Chemistry and Biology (ESCOM, Leiden, Proceeding of the Eleventh American Peptide Symposium, UCSD, La Jolla, CA (July 9-14, 1989), 1990, pp. 978-980.